Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

RAPT Therapeutics, Inc. - Common Stock (NQ:RAPT)

29.35 -0.86 (-2.85%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about RAPT Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
RAPT Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Presents Update from its Phase 1/2 Clinical Trial for FLX475 as Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Cancer
Data Presented at ESMO Immuno-Oncology Congress 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
4 Analysts Have This to Say About RAPT Therapeutics
 
Via Benzinga
RAPT Therapeutics to Present FLX475 Phase 1/2 Data at the European Society for Medical Oncology (ESMO) Immuno-Oncology Annual Congress
From RAPT Therapeutics, Inc.
Via GlobeNewswire
Expert Ratings For RAPT Therapeutics
  RAPT Therapeutics (NASDAQ:RAPT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2022
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Delta Apparel, Farfetch, American Software And Some Other Big Stocks Moving Lower On Friday
U.S. stocks traded mixed, with the Dow Jones gaining more than 80 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Recap: RAPT Therapeutics Q2 Earnings
  RAPT Therapeutics (NASDAQ:RAPT) reported its Q2 earnings results on Thursday, August 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
This Mid-Cap Firm Can Potentially Offer Biggest Oral Drug In Atopic Dermatitis, Cantor Thinks So
 
Via Benzinga
Why InMed Pharmaceuticals Shares Tumbled 28%; Here Are 67 Biggest Movers From Friday
Gainers AGBA Group Holding Limited (NASDAQ: AGBA) gained 50.7% to close at $6.78 on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Recap: RAPT Therapeutics Q1 Earnings
RAPT Therapeutics (NASDAQ:RAPT) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
From RAPT Therapeutics, Inc.
Via GlobeNewswire
MacroGenics To Surge 138%? Plus This Analyst Sees $50 For Exact Sciences
BMO Capital boosted the price target on MacroGenics, Inc. (NASDAQ: MGNX) from $5.7 to $16. BMO Capital analyst Etzer Darout upgraded the stock from Market Perform to Outperform. MacroGenics shares... 
Via Benzinga
Why Apyx Medical Shares Dipped Over 60%; Here Are 123 Biggest Movers From Yesterday
Gainers 
Via Benzinga
RAPT Therapeutics Reports Third Quarter 2022 Financial Results
Company maintains strong cash position of $195.4 million 
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences
From RAPT Therapeutics, Inc.
Via GlobeNewswire
RAPT Therapeutics Strengthens Leadership Team with Two New Key Hires
From RAPT Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) shares moved upwards by 20.1% to $1.79 during Wednesday's after-market session. The market value of their outstanding shares is at $31.6 million. 
Via Benzinga
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for RAPT Therapeutics: Here's What You Need To Know
  HC Wainwright & Co. has decided to maintain its Buy rating of RAPT Therapeutics (NASDAQ:RAPT) and raise its price target from $50.00 to $53.00. Shares of RAPT Therapeutics are trading up 14.98% over... 
Via Benzinga
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday
  WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests... 
Via Benzinga
What 4 Analyst Ratings Have To Say About RAPT Therapeutics
Analysts have provided the following ratings for RAPT Therapeutics (NASDAQ:RAPT) within the last quarter: 
Via Benzinga
Starbucks And 2 Other Stocks Insiders Are Buying
Although the Dow Jones jumped by more than 400 points on Friday, there were a few notable insider trades. 
Via Benzinga
RAPT Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q4, RAPT Therapeutics (NASDAQ:RAPT) posted sales of $756.00 thousand. Earnings were up 3.87%, but RAPT Therapeutics still reported an... 
Via Benzinga
This Healthcare Stock Tumbled 43%; Here Are 88 Biggest Movers From Yesterday
Gainers Athersys, Inc. (NASDAQ: ATHX) climbed 71.1% to close at $0.3250 on Thursday after gaining 10% on Wednesday. Athersys is expected to release its Q2 financial results on Thursday, August 11,... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 435 companies set new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.